Brief Communication
demonstrate better in vitro activity against isolates resistant to ceftazidime, cefepime and P/T studied across the world. [2] In this study, we evaluated the in vitro efficacy of C/T against P. aeruginosa collected from Indian hospitals. Further in silico analysis was performed to support the in vitro findings.
matErIals and mEtHods

In vitro analysis
In this study, we determined the antimicrobial susceptibility for a total of 149 invasive clinical isolates of P. aeruginosa for the most commonly used antimicrobials including C/T. Isolates collected across various centers in India were tested. These isolates were sourced from the bloodstream, intra-abdominal and UTIs collected between the year 2013 and 2014. Broth microdilution was performed to determine the minimum inhibitory concentration (MIC) against various antimicrobials and results were interpreted according to the CLSI 2016 breakpoint interpretative criteria. [3] E. coli ATCC 35218 and P. aeruginosa ATCC 27853 were used as quality control organisms.
In silico analysis
The 3D structure of P. aeruginosa ampC was retrieved from the Protein Data Bank (PDB) with the PDB ID 4GZB. [4] The SMILES of C/T, and Piperacillin were retrieved from PubChem database with CIDs 53234134, 123630 and 43672, respectively. The 3D structures were converted to PDB format structure using OpenBabel. Molecular docking was performed using AutoDock 4.2. Hydrogen and necessary charges were charges added to the protein followed by torsion to the drugs. The grid was fixed around the active site, and AutoGrid was performed. Finally, AutoDock was performed using Lamarckian Genetic Algorithm in 10 runs. The docking was performed thrice, and average binding energy was calculated.
rEsults
In vitro analysis
Antimicrobial susceptibility profiles of the study isolates against the tested agents are summarised in Table 1 . MIC 50 and MIC 90 for P. aeruginosa were 1/4 μg/ml and ≥16/4 μg/ ml, respectively. Among the β-lactam/β-lactamase inhibitor, overall susceptibility was 67%, 55% and 51% for C/T, P/T and C/S, respectively. The variations in the susceptibility rates were 16% for C/T versus C/S and 12% for C/T versus P/T, respectively. Interestingly, 33% susceptibility was noted for C/T against isolates that were resistant to P/T, indicating the higher activity of C/T. However, the number of isolates analysed are less. Hence, a large number of isolates needs to be tested to prove the superiority of C/T over other agents.
In silico analysis
The docking analysis has shown higher binding affinity for ampC with piperacillin and least binding affinity for ampC with ceftolozane. However, the binding affinity of-6.47 kcal/mol for ampC and tazobactam was noted, which was found to be in between the ampC and ceftolozane (−4.38) and ampC and piperacillin (−7.22). AmpC found to interact with ceftolozone through 13 amino acids (GLN120, THR290, SER289, ASN288, SER64, THR320, ASN321, SER319, ASN344, ASN347, PRO346, ALA348 and ARG350) and seven polar contacts. While for piperacillin, ampC found to react with 12 amino acids (TYR223, GLN129, ASN153, SER64, LYS67, LEU119, ASN344, TYR131, ALA293, ARG350, ASN347 and THR290) and three polar contacts. However, ampC with tazobactam showed interaction with 12 amino acids (SER319, ALA293, THR317, ASN344, TYR345, THR290, PRO346, ASN347, ASN288, SER289, ARG350 and ALA348) and eight polar contacts [ Figure 1a -c]. 
dIscussIon
This study finding is in concurrence with the previously published in vitro studies; wherein, the susceptibility rates and MIC 50 were almost similar as summarised in Table 2 .
Further, this study data suggest that C/T will be effective than P/T and C/S, especially for managing infections due to drug-resistant P. aeruginosa. Buehrle et al. have attributed improved C/T activity, as it evades ampC-mediated hydrolysis in P. aeruginosa. [8] Further, ceftolozane escapes from the efflux mechanisms. It is well known that majority of the drug resistance in P. aeruginosa is due to over expression of efflux pumps. The notable difference in the activity of C/T over P/T and C/S could be due to overcoming these resistance mechanisms such as ampC and efflux. This finding has to be validated with testing a large number of isolates with known resistance mechanisms. However, the studies have shown mutations in the ampC confer resistance to C/T. Although it is intrinsic, mutations in the ampC have variable effects in the MIC of other cephalosporin agents as well, including C/T. [9, 10] This is the first report of testing C/T against clinical isolates from India showing 30% incremental increase in the susceptibility for beta-lactamase producers. This finding suggests about 33% of the P/T-resistant isolates can still be treated effectively with C/T. From the docking analysis, hydrolysis rate of piperacillin by ampC was higher due to the higher binding affinity, leading to hydrolysis of piperacillin. However, ceftolozane is less prone to hydrolysis by ampC due to the less binding affinity, results in the effective activity of ceftolozane. This concurs with the in vitro susceptibility testing, wherein ceftolozane activity is superior to piperacillin. To conclude, as the development of newer agents are minimal, the utility of higher antibiotics (carbapenems and colistin) can be minimised using C/T when available in India and found susceptible against the beta-lactamase producing P. aeruginosa.
conclusIon
Antimicrobial resistance has become a major concern across the world. C/T is a new beta-lactam/beta-lactamase inhibitor-based antimicrobial agent, which has shown to have an excellent antipseudomonal activity, as it by passes ampC-mediated resistance. Among the β-lactam/β-lactamase inhibitor, the activity of C/T was observed to be superior to P/T and C/S. This overall in vitro and in silico analysis elucidates that the C/T could be a better alternative to P/T for the treatment of infections due to P. aeruginosa.
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